W. L. Gore & Associates of Flagstaff has launched a new vascular graft for vascular access. Designed for early cannulation within 24 hours after implantation, the Gore Acuseal expands treatment options for earlier removal or possible avoidance of a central venous catheter — a major source of infection for hemodialysis patients.
The Food and Drug Administration approved the Gore vascular graft in April 2013.
“The new Gore Acuseal Vascular Graft represents Gore’s long standing commitment to developing innovative graft products that improve patient care,” said Cress Whitfield, sales leader, surgical vascular, Gore Medical. “By offering a graft that allows for early cannulation, physicians can provide patients with better treatment options while still benefitting from the uncompromised handling offered by Gore’s vascular grafts.”